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Abstract
Background: Our aim was to compare survival of the various treatment modality groups of chemotherapy and/or
radiotherapy in relation to SEMS (self-expanding metal stents) in a retrospective case-control study. We have made
the hypothesis that the administration of combined chemoradiotherapy improves survival in inoperable
esophageal cancer patients.
Methods: All patients were confirmed histologically as having surgically non- resectable esophageal carcinoma.
Included were patients with squamous cell carcinoma, undifferentiated carcinoma as well as Siewert type I–but not
type II - esophagogastric junctional adenocarcinoma. The decision to proceed with palliative treatments was taken
within the context of a multidisciplinary team meeting and full expert review based on patient’s wish, co-morbid
disease, clinical metastases, distant metastases, M1 nodal metastases, T4-tumor airway, aorta, main stem bronchi,
cardiac invasion, and peritoneal disease. Patients not fit enough to tolerate a radical course of definitive chemo-
and/or radiation therapy were referred for self-expanding metal stent insertion. Our approach to deal with
potential confounders was to match subjects according to their clinical characteristics (contraindications for
surgery) and tumor stage according to diagnostic work-up in four groups: SEMS group (A), Chemotherapy group
(B), Radiotherapy group (C), and Chemoradiotherapy group (D).
Results: Esophagectomy was contraindicated in 155 (35.5%) out of 437 patients presenting with esophageal
cancer to the Department of General and Abdominal Surgery of the University Hospital of Mainz, Germany,
between November 1997 and November 2007. There were 133 males and 22 females with a median age of 64.3
(43-88) years. Out of 155 patients, 123 were assigned to four groups: SEMS group (A) n = 26, Chemotherapy group
(B) n = 12, Radiotherapy group (C) n = 23 and Chemoradiotherapy group (D) n = 62. Mean patient survival for the
4 groups was as follows: Group A: 6.92 ± 8.4 months; Group B: 7.75 ± 6.6 months; Group C: 8.56 ± 9.5 months, and
Group D: 13.53 ± 14.7 months. Significant differences in overall survival were associated with tumor histology (P =
0.027), tumor localization (P = 0.019), and type of therapy (P = 0.005), respectively, in univariate analysis. Treatment
modality (P = 0.043) was the only independent predictor of survival in multivariate analysis. The difference in
overall survival between Group A and Group D was highly significant (P < 0.01) and in favor of Group D. As
concerns Group D versus Group B and Group D versus Group C there was a trend towards a difference in overall
survival in favor of Group D (P = 0.069 and P = 0.059, respectively).
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Background
Accurate information regarding the proportion of
patients with esophageal cancer in whom surgery is con-
traindicated is difficult to obtain. This largely reflects
variations in the selection of patients for palliative treat-
ment modalities. In the Western world, more than half
the patients with esophageal cancer are not amenable to
surgery as they usually present with severe comorbidity
and an advanced stage of disease [1].
The choice of treatment must be tailored to the indi-
vidual and will depend on the location and stage of the
tumor, as well as the overall health of the patient.
Four RCT’s [2-5] and one meta-analysis [6] compared
brachytherapy, laser ablation therapy and argon beam
coagulation (APC) therapy with self-expanding metal
stents within the context of esophageal cancer palliation.
The aforementioned studies present symptomatic
patient relief as the primary outcome and patient survi-
val as the secondary. Only one of the studies [3] pro-
vides data for external beam radiation therapy, but
patients are collectively analyzed with those who under-
went APC.
It has also been suggested that combination chemora-
diotherapy may improve response rates and thus survi-
val, although evidence is limited [7]. A study providing a
straightforward comparison between chemotherapy and/
or radiotherapy and SEMS is lacking.
We have made the hypothesis that the administration
of combined chemoradiotherapy improves survival in
inoperable esophageal cancer patients. Our aim was to
specify survival of the various treatment modalities in
relation to SEMS in a retrospective case-control study.
Methods
From November 1997 to November 2007, a total of 437
patients presented to our institution with histologically
proven esophageal carcinoma. Esophagectomy was con-
traindicated in 155 (35.5%) patients (133 males, 22
females) with a median age of 64.3 (43-88) years. This
represents a group of individuals for whom a minimum
of 4 years of follow-up data was possible.
Reasons of incurability were distant metastases (n =
54; 34.8%), local tumor spread (n = 58; 37.4%) and pre-
existent cardiopulmonary diseases (n = 26; 16.8%).
Seventeen (11%) patients presented further reasons of
incurability. Of these, 5 patients refused surgery, and 5
were excluded from surgery as they did not have an
adequate substitute organ for reconstruction and
esophagoplasty. In 7 patients, the risk of esophagectomy
was considered too high due to their poor general
health status.
After histological confirmation, all patients underwent
a preoperative diagnostic work-up, in addition to com-
puted tomography of the neck, thorax, and abdomen,
which included endosonography of the esophagus, bar-
ium swallow, transabdominal sonography of the abdo-
men, as well as positron emission tomography (PET), as
previously described [8]. A conventional X-ray examina-
tion of the thorax and laboratory tests with the tumor
markers carcinoembryonic antigen (CEA), Ca 19-9, Ca
72-4, and Alpha-Feto-Protein (AFP) were routinely
performed.
Inclusion and exclusion criteria
All patients were confirmed histologically as having eso-
phageal carcinoma. Included were patients with squa-
mous cell carcinoma (SCC), undifferentiated carcinoma
(UDC), as well as Siewert type I–but not type II–eso-
phagogastric junctional adenocarcinoma (ADC) [9].
The decision to proceed with palliative treatments was
taken within the context of a multidisciplinary team
meeting and full expert review based on patient’sw i s h ,
co-morbid disease, distant metastases, M1 nodal metas-
tases, and T4 tumor.
Hematogenic and lymphogenic metastases were docu-
mented by computed tomography (CT) examination,
PET scan and endosonographic ultrasound. In summary,
a CT diagnosis of T4-tumor stage made an R0 resection
impossible.
Standard indicators defining a patient as medically
inoperable included baseline forced expiratory volume
in the first second of expiration (FEV1) of less than 40%
predicted, carbon monoxide diffusing capacity of less
than 40% predicted, baseline hypoxemia or hypercapnia,
severe pulmonary hypertension; diabetes mellitus with
end-organ damage; severe cerebral, cardiovascular, or
peripheral vascular disease; or severe, chronic heart
disease.
Multidisciplinary team strategy
Patients not fit enough to tolerate a radical course of
definitive chemotherapy and/or radiation, or those who
needed rapid relief of their dysphagia (swallowing may
deteriorate because of radiation induced edema and
swelling of the tumor) were referred for self-expanding
metal stent (SEMS) insertion. Radiochemotherapy was
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courses of combined fluorouracil and cisplatin plus
5,000 cGy of radiation therapy) [10]. In brief, patients
without distant metastases underwent external beam
radiotherapy with a dose of 50-60 Gy and, whenever
possible, an additional brachytherapy of up to 68 Gy. In
selected patients with previous cancer and consecutive
radiotherapy (e.g. oropharyngeal, laryngeal cancer, etc.),
these doses had to be individually adapted. Patients
receiving chemotherapy alone were given a combination
of fluorouracil and cisplatin, providing no contraindica-
tions were present. Patient groups were not randomized.
Locally inoperable squamous cell carcinoma was trea-
ted by chemoradiotherapy, radiation therapy alone, or
palliative chemotherapy in cases of distant metastases,
whereas advanced or metastasized adenocarcinoma was
treated by chemotherapy or chemoradiotherapy.
Control for confounding variables
Data of patients with esophageal carcinoma undergoing
the four main treatment modalities (SEMS, chemother-
apy and/or radiotherapy) were matched according to
clinical characteristics (contraindications for surgery)
and tumor stage by diagnostic work-up.
The confounding variables were chosen according to
the Standardization or Adjustment method: we applied
the cumulative proportion surviving rates generated in
each of our four strata (stent, chemotherapy, radiother-
apy, chemoradiotherapy) to the same “standard” theore-
tical population. This standard population was created
so that the frequency of the confounder is identical
between each group of patients; this was achieved by
applying sequential filters to the Microsoft Excel
database.
According to their treatment modality, patients were
assigned to four groups: SEMS group (A), Chemother-
apy group (B), Radiotherapy group (C), and Chemora-
diotherapy group (D).
According to the study hypothesis, the control group
included patients in whom a self expandable stent had
been inserted.
Definitions
In patients with histologically proven esophageal carci-
noma, the following prognostic variables were
recorded, American Society of Anesthesiologists (ASA)
classification (I-IV) according to the anesthesiology
evaluation, body mass index (BMI) based on body
weight and height in kg/m
2, and the nutritional status
including tobacco and/or alcohol abuse. Tobacco
abuse was defined by the consumption of at least 5
cigarettes a day over a period of > 1 year, whereas
alcohol abuse was defined by the regular intake of
beer, wine or hard drinks, at least every second day.
Among the comorbidities, cardiovascular risk factors
were defined as a history of coronary heart disease, or
myocardial infarction, arterial hypertension, valvular
disease (> II°), arrhythmia requiring therapy (> III°
according to the Lown classification), heart failure
NYHA (New York Heart Association) > grade II, and
peripheral occlusive arterial disease (> IIb according
to Fontaine). A history of chronic obstructive pulmon-
ary disease (COPD), regular tobacco consumption,
and/or the use of bronchospasmolytics were subsumed
under pulmonary diseases. The preoperative evalua-
tion of the vital capacity (VC) and the forced expira-
tory volume in 1 s (FEV1 = Tiffeneau test) served to
ensure a more accurate assessment. Preexisting cirrho-
sis of the liver (≥CHILD-Pugh A) was defined as hepa-
tic disease, and determined on the basis of the
measurement of serum albumin (g/dl), serum bilirubin
( m g / d l ) ,Q u i c kv a l u e( % ) ,a n dt h ep r e s e n c eo fa s c i t e s
or encephalopathy. The evaluation of additional risk
factors included the prevalence of diabetes mellitus
(insulin-dependent or requiring drug therapy), and the
history of a secondary carcinoma.
For a better comparison of staging procedures, the
esophagus was considered in thirds, according to the
endoscopic location of the tumor: upper third: dental
front to 20 cm; middle third: 20-30 cm; lower third: 30
cm to the Z-line.
The various study parameters were coded as follows:
Procedures: 1 = explorative laparotomy/laparoscopy, but
no resection; 2 = none; 3 = primarily neoadjuvant inten-
tion; 4 = surgical exploration, but no resection; 5 =
explorative thoracotomy/thoracoscopy, but no resection.
Tumor histology: 1 = squamous cell cancer; 2 = adeno-
carcinoma; 3 = undifferentiated carcinoma. Contraindi-
cation for surgery: 1 = metastases; 2 = local tumor
spread; 3 = cardiopulmonary; 4 = pulmonary; 5 = car-
diac; 6 = esophageal substitute not available; 7 = tumor
spread and poor general condition; 8 = tumor spread
and cardial disease; 9 = patient refuses surgery; 10 =
mucosal resection; 11 = metastases and poor general
condition; 12 = patient refuses surgery and poor general
condition. Reasons for non-surgical management: 1=
metastases; 2 = locally not resectable; 3 = cardiopulmon-
ary contraindication; 4 = other. Metastasis site: 1=
liver; 2 = lung; 3 = lung + liver; 4 = M1 lymph nodes; 5
= diffuse; 6 = peritoneal carcinosis; 7 = bone; 8 = brain;
9=s k i n .Type of metastases: 1=h e m a t o g e n e o u s ;2=
lymphatic. Treatment modality: 1 = stent; 2 = che-
motherapy; 3 = radiation; 4 = radio-chemotherapy; 5 =
tracheostomy; 6 = mucosectomy. For all clinical charac-
teristics, the presence of the variables mentioned was
declared 1, and the absence 0.
Approval for the study was obtained from the hospital
ethics committee.
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In order to validate our patient selection with confound-
ing variables, two different statistical tests were applied:
1) Kruskal-Wallis ANOVA by Ranks test (Median test)
was used in order to compare the clinico-pathological
parameters (numerical) of patients among the various
groups of therapy and compute post-hoc comparisons
of mean ranks of all pairs attributed to by groups and 2)
Spearman’s correlations were also used to analyze the
distribution of the clinico-pathological parameters
(coded in categories) separately in each group of
therapy.
A multivariate analysis was performed under Cox’s
Proportional Hazard Model considering all factors that
gained statistical significance (P < 0.05) in univariate
analysis under the same model. Variables that reached
significance in the multivariate model were considered
as predictors of survival. In order to compare survival
between two samples, the Cox’s F-test was employed. So
as to validate our results in terms of cumulative propor-
tion surviving, sample size calculation was performed
with a type I error rate (Alpha) 0.05 and power goal
0.80 by applying the two-tailed Log-Rank test.
Significance was considered at a level < 0.05. Statistical
release 7 (Statsoft, Tulsa, USA) was used for statistical
analysis.
Results
In relation to all patients presenting with esophageal
cancer from November 1997 to November 2007, the
proportion of inoperable patients was higher in SCC’s
(23.8%; n = 104/437) as compared to ADC’s (10.5%; n =
46/437) (in addition 5 patients with UDC). Both tumor
entities revealed different reasons of inoperability: In
patients with SCC, local tumor spread predominated
with 45.7%, whereas in the majority of patients with
ADC (58.7%), inoperability was due to hematogeneous
metastases. Cardiopulmonary diseases causing contrain-
dication for surgery were equally distributed among
both tumor entities (17.1% in patients with SCC and
17.4% in patients with ADC).
The course of the disease was ascertained in 152 out
of 155 (98%) patients by December 31st 2010; no data
documenting the course were available in 3 patients at
that time. One hundred and forty-eight patients had
died from their malignancy; of the remaining 7 patients,
4 were alive and 3 were lost from follow-up. All 4
patients alive at the time of last follow-up had initially
presented with a locally inoperable SCC and had under-
gone radiochemotherapy.
Six patients who underwent mucosectomy (n = 2) and
tracheostomy (n = 1) or were lost from follow-up (n =
3) were not included in the analysis. The respective
numbers of patients for SCC, ADC and UDC were 104,
46 and 5. According to the diagnostic work-up, tumor
stage was IIA in 17 patients, IIB/III in 76 patients and
IV in 54 patients. Contraindications for surgery were
cardiopulmonary status in 26 patients, metastasis and
tumor spread in 119, surgery refusal by 5, and no
chance of esophageal substitution in five patients.
Brachytherapy was administered to 2 patients in group
C and to 16 patients in group D. Seven patients in
g r o u pB ,1 0i ng r o u pC ,a n d3 7p a t i e n t si ng r o u pD
completed their allocated treatment modality.
UDC patients were excluded since there were missing
data in 3 (tumor stage), while the remaining 2 patients
were excluded during the selection process.
In applying the sequential filters for confounding vari-
ables, only 123 out of 155 patients were considered for
the analysis. We took care to include only patients with-
out missing data, in terms of contraindications for sur-
gery and TNM-stage by applying sequential filters to the
Microsoft Excel database (Figure 1). Contraindications
for surgery were divided into 3 categories: a) cardiopul-
monary, b) metastasis/non-resectable and c) other.
Patients were considered accordingly by an analogy 1/5/
1 (paralleling the rates among the 155 patients) in each
of the 3 patient classes of the TNM-stage (IIA, IIB/III,
IV) which were considered respectively by an analogy of
2/9/7 (paralleling the rates among the 155 patients) (Fig-
ure 1). These sequential steps reduced the total of 155
patients by 8 patients (missing data), 19 patients by
“TNM-stage” filtering, 2 patients by “contraindications
for surgery” filtering and 3 patients lost to follow up
(Figure 1). The remaining 123 patients were assigned to
four groups: SEMS group (A) n = 26 (SCC:10/ADC:16),
Chemotherapy group (B) n = 12 (SCC:10/ADC:2),
Radiotherapy group (C) n = 23 (SCC:11/ADC:12), Che-
moradiotherapy group (D) n = 62 (SCC:52/ADC:10).
For every patient in group B, approximately 2 patients
in groups A and C, and 5 in group D were analyzed in
terms of survival.
As concerns the allocation of clinico-pathological
characteristics among the 4 groups, all 21 parameters
were equally distributed in terms of age, tumor localiza-
tion, type of metastasis, histology, and cardiopulmonary
status (Table 1).
Overall median and mean patient survival was 6
months and 10.89 ± 12.63 months, respectively. The
respective numbers for the 4 groups were as follows:
Group A: 3/6.92 ± 8.4 months; Group B: 7/7.75 ± 6.6
months; Group C: 4/8.56 ± 9.5 months and Group D: 8/
13.53 ± 14.7 months. Overall survival for the 4 groups is
depicted in Table 2.
Twenty-one variables were analyzed in univariate analy-
sis of survival: gender, age, BMI, vital capacity (VC), FEV1,
cTNM-classification, ASA-classification, nutritional status,
tobacco consumption, alcohol intake, diabetes, Child-Pugh
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noma, histopathology, tumor localization, contraindication
for surgery, cause of inoperability, site of metastasis and
type of metastasis. Significant differences in overall survi-
val were associated with tumor histology (P = 0.027),
tumor localization (P = 0.019), and type of therapy (P =
0.005), respectively (Table 3).
In multivariate Cox’s Proportional Hazard regression
analysis of survival, the model including the predictors
in univariate analysis gained statistical significance (P <
0.001), but treatment modality (P = 0.043) was the only
independent predictor of survival (Table 4).
With regard to the 12-month hazard rate/standard
error of hazard rate for the 4 treatment groups: Group
A = 0.14/0.07, Group B = 0.16/0.10, Group C = 0.15/
0.06, and Group D = 0.04/0.01.
The difference in overall survival between Group A
and Group D was highly significant (P <0 . 0 1 ) ,a n di n
favor of Group D. Comparing Group D versus Group B
and Group D versus Group C, the difference in overall
survival was marginally significant, and in favor of
Group D (P =0 . 0 6 9a n dP = 0.059, respectively). The
other possible comparisons in overall survival between
Groups did not reach statistical significance (Figure 2).
Aiming to establish a 2-year difference in overall sur-
vival of 24.3% vs. 3.8% for groups D and A respectively,
there was a need for 26 patients per treatment group.
The respective number for group D vs. C was 23
patients (24.3% vs. 0%), and for group D vs. B, it was 61
patients (24.3% vs. 8.6%). All the aforementioned com-
parisons of overall survival between groups fulfilled the
sample size calculation, with the exception of one
(group D: 62 patients vs. group B: 12 patients).
In order to investigate the rationale of our multidisci-
plinary team strategy to assign more adenocarcinoma
patients to chemotherapy alone (n = 12) than to che-
moradiotherapy (n = 9), survival curves of these two
groups were compared. No statistical significant differ-
ence in overall survival was observed (P = 0.589). The
same applied to squamous cell carcinoma patients
undergoing chemoradiotherapy (n = 55) versus radio-
therapy alone (n = 10) (P = 0.405).
Discussion
In the setting of care in inoperable esophageal cancer,
the combination of chemoradiotherapy was more effica-
cious than any other treatment modality, and undoubt-
edly superior to the use of SEMS in terms of patient
Figure 1 Only patients without missing data (in terms of the confounding variables) were included by applying sequential filters to
the Microsoft Excel database. Contraindications for surgery were divided into 3 categories: a) cardiopulmonary (CP), b) metastasis/non-
resectable (M/NR) and c) other. Patients were considered accordingly by an analogy 1/5/1 (paralleling the rates among the 155 patients) in each
of the 3 patient classes of the TNM-stage (IIA, IIB/III, IV) which were considered respectively by an analogy of 2/9/7 (paralleling the rates among
the 155 patients). These sequential steps reduced the total 155 patients by 8 patients (missing data), 19 patients by “TNM-stage” filtering, 2
patients by “contraindications for surgery” filtering and by 3 patients lost to follow up. The remaining 123 patients were assigned to four groups.
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and 5-year survivors.
Though the clinico-pathological characteristics among
patients of the 4 groups were not significantly different,
there were distinct differences observed in some. This is
mainly attributed to the multidisciplinary team strategy:
1) Patients not fit enough to tolerate a radical course of
definitive chemotherapy and/or radiation were referred
for self-expanding metal stent insertion, and 2) Patients
with locally inoperable squamous cell carcinoma were
treated by chemoradiotherapy, radiation therapy alone
or chemotherapy in cases of distant metastases, whereas
patients with advanced adenocarcinoma were treated by
chemotherapy or chemoradiotherapy. Despite this
Table 1 Comparison of clinico-pathological characteristics among the 4 groups of treatment modality
Variable (continuous) Kruskal-Wallis ANOVA by Ranks test
(Median test) Mean ± SD
P-value
Age A SEMS
B Chemo
C Radiation
D C/R
69.57 ± 10.08 P = 0.017 (SEMS vs. C/R*
P = 0.013)
67.00 ± 4.30
66.44 ± 8.57
61.05 ± 9.74
BMI 24.87 ± 4.27 P = 0.466
25.91 ± 5.65
25.70 ± 4.00
24.81 ± 5.11
Vital capacity (VC) 3.54 ± 1.08 P = 0.287
3.75 ± 0.93
2.75 ± 1.28
3.78 ± 0.95
FEV1 32.53 ± 33.53 P = 0.306
41.29 ± 33.42
38.86 ± 30.13
46.98 ± 28.11
Variable (categorical) Distribution of variable categories among
groups of therapy
Spearman Rank Order Correlations P-value
cTNM-classification -0.124360 0.165
ASA-classification -0.017661 0.876
Nutrition 0.166002 0.244
Smoking 0.080980 0.387
Alcohol 0.082105 0.380
Child-Pugh score 0.033203 0.724
Pulmonary status 0.226517 0.013
Cardiovascular status -0.226854 0.013
Diabetes -0.043337 0.642
Secondary carcinoma 0.095611 0.286
Gender -0.146058 0.095
Histology -0.348704 0.001
Localization -0.259496 0.002
Contraindications for
surgery
0.032170 0.715
Causes of
inoperability
0.128822 0.142
Site of metastases -0.060909 0.566
Type of metastases 0.224707 0.032
SD: Standard deviation; SEMS: Self-expandable metallic stents; C/R*: Chemo-Radiotherapy; BMI: body mass index; ASA: American Society of Anesthesiologists
classification; FEV1: Forced expiratory volume in 1 s
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aforementioned groups were not significantly different.
Although various studies [9,11] have described histolo-
gic differentiation as an independent prognostic factor
after R0 resection, our results showed no evidence of
significance supporting this fact in inoperable esopha-
geal cancer. The only decisive predictor of survival was
the type of treatment modality as shown in our multi-
variate analysis. However, in cases of rather favorable
prognosis among inoperable patients, palliation and sur-
vival have to be considered, whereas in individuals with
rather unfavorable findings and a projected limited sur-
vival, palliation should be the main focus. This includes
rapid and effective alleviation of symptoms as well as
avoidance of possible complications and repeated inter-
ventions, thus improving or maintaining patients’ quality
of life.
Our study, involving an inoperable patient cohort,
yielded similar results to those of other prospective stu-
dies [12,13] and a meta-analysis of randomized trials
[14], which evaluated combined chemoradiotherapy ver-
sus radiotherapy alone in patients with localized esopha-
geal carcinoma.
Unlike our data with four long-term survivors, who
had initially presented with locally inoperable cancer,
better survival following radiochemotherapy has been
reported in the literature for patients primarily excluded
from surgery due to preexistent comorbidity [15]. In
some studies, however, life-expectancy was unfavorable
in patients with cT4-tumors [14,15].
This study was conducted, despite the risk of selection
bias, since a randomized controlled trial resolving the
issue is hardly, if ever, feasible. It is not without its
drawbacks, mainly: 1) It is not a prospective rando-
mized, but a retrospective case-control study; 2) The
fact, that cT-, cN- and cM-categories in inoperable dis-
ease were proven by CT, endosonographic ultrasound,
PET scan, and in selected patients by staging laparo-
scopy/laparotomy or thoracoscopy/thoracotomy, may be
a source of bias because clinical and histological stage
may differ; 3) Other established treatment modalities,
such as brachytherapy only (without combined radiation
therapy) or Argon beam coagulation were not included
as main or accessory measures for palliative treatment,
although these did not form part of the research ques-
tion; 4) Even though patient data was matched to deal
with the confounders of contraindications to surgery
and stage of disease, the fact that patients received a
stent because they were not able to tolerate chemora-
diotherapy and had significant dysphagia can potentially
affect the outcome; 5) Patients’ symptom relief and pro-
cedural complications were not included due to
Table 2 Cumulative proportion surviving of the 4 groups
Months Chemo-radiotherapy Chemotherapy Radiation Stent
6 60.60% 43.47% 58.33% 38.46%
12 39.39% 34.78% 25.00% 19.23%
18 30.30% 13.04% 08.33% 07.69%
24 24.24% 08.69% 0% 03.84%
30 10.60% 04.34% 01.92%
36 07.57% 02.17% 00.96%
42 06.06% 0% 0%
48 05.19%
54 04.32%
60 03.46%
Table 3 Univariate analysis of survival
Beta Wald
statistic
P-value*
ASA-classification -0.034372 0.034097 0.853501
Nutrition status -0.059647 0.310746 0.577226
Smoking -0.282645 2.403644 0.121063
Alcohol consumption -0.294566 2.635858 0.104485
Hepatopathy 0.066506 0.091186 0.762676
Pulmonary disease -0.062020 0.114867 0.734672
Cardial disease -0.276026 2.215080 0.136678
Diabetes -0.241763 1.005458 0.316001
Secondary carcinoma 0.196181 0.924205 0.336381
Vital Capacity (VC) -0.239513 2.552092 0.110158
FEV1 -0.296171 3.468683 0.062550
Age 0.008591 0.774818 0.378737
Gender 0.319681 1.808111 0.178745
Procedure 0.081361 0.364907 0.545798
Histology 0.362451 4.884958 0.027099
Localization 0.241270 5.437840 0.019711
Contraindication
for surgery
-0.041959 1.555456 0.212341
Causes of incurability -0.053454 0.340351 0.559631
Site of metastases 0.087241 1.488161 0.222511
Type of metastases -0.346926 2.826217 0.092746
Therapy -0.199524 7.805245 0.005213
BMI -0.003725 0.050582 0.822056
*P-values in bold depict statistical significance
BMI: body mass index; ASA: American Society of Anesthesiologists
classification; FEV1: Forced expiratory volume in 1 s
Table 4 Multivariate analysis of survival
Beta Wald
statistic
P-value*
Histology 0.077891 0.142777 0.705539
Localisation 0.167822 1.988769 0.158479
Type of therapy -0.157421 4.059833 0.043923
*P-values in bold depict statistical significance
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by a recent meta-analysis [6].
Conclusions
In summary, the prognosis of inoperable esophageal
cancer seems to be highly dependent on the suitability
of the induction of patient-specific therapeutic measures
and is better when chemoradiotherapy is applied,
though this is not proven by randomized data in our
patient cohort.
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